Systemic immune activation in hereditary cancer predisposition syndromes : a cross-sectional study

Kelemen, István and Horti-Oravecz, Klaudia and Bozsik, Anikó and Pócza, Tímea and Papp, János and Likó, István and Neuperger, Patrícia and Balogh, Fanni and Kemény, Ágnes and Nagy, Petra and Vereczki, Viktória and Pósa, Szonja Polett and Pongor, Lőrinc Sándor and Kövesdi, Dorottya and Butz, Henriett and Patócs, Attila Balázs and Szebeni, Gábor János and Grolmusz, Vince Kornél (2026) Systemic immune activation in hereditary cancer predisposition syndromes : a cross-sectional study. BMC MEDICINE, 24 (1). no.-467. ISSN 1741-7015

Preview

Text KelemenI_2026.pdf - Published Version Available under License Creative Commons Attribution. Download (8MB) | Preview

Abstract

Immune surveillance mechanisms contribute to the elimination of precancerous lesions in hereditary cancer predisposition syndromes (HCPSs). By combining single-cell transcriptomics, multiparametric mass cytometry and cytokine profiling of the systemic immune environment in 391 individuals among whom 227 are living with HCPSs we investigated phenotypic alterations in cancer-free individuals with HCPS. A decrease in peripheral B cell abundance and their more differentiated phenotype have been confirmed both in breast cancer patients with germline pathogenic variants in BRCA1 (gpath(BRCA1)) and in patients living with Lynch syndrome (LS). Pre-cancer women with gpath(BRCA1) exhibited an activated phenotype of multiple immune cell lineages, similar to those with manifest disease. In LS, B cell phenotypes exhibited the largest changes in response to cancer eradication, while increased peripheral IL-6 levels was detected even in presymptomatic individuals with LS. HCPS-specific differences in the phenotype of the systemic immune system might be leveraged in future risk-reducing strategies.

Actions (login required)

View Item